0%

est. 2Y upside i

HealthcareSeries A

Arya Health builds AI-powered digital agents that eliminate the administrative burden in post-acute care-so caregivers and coordinators can focus on patients, not processes. Purpose-built for home health, home care, and hospice, Arya integrates with leading EMRs to automate scheduling, compliance, onboarding, and more.

Rank

#2827

Sector

Healthcare Technology

Est. Liquidity

~5Y

Data Quality

Data: Low

Equity upside cannot be reliably estimated due to missing revenue and valuation data.

Last updated: July 3, 2026

Bull (15%)0%

Valuation unknown; typical Series A bull case assumes 3-5x revenue multiple, but revenue data missing. High TAM and AI adoption could drive growth.

Base (50%)0%

Without revenue or growth data, base case upside cannot be quantified. Company is early-stage with high incumbent threat.

Bear (35%)-100%

Preference stack of $25M overhang could wipe out common equity if exit < $25M. Bear scenario assumes failure to scale or acquisition at low multiple.

Est. time to liquidity~5.0 years

Preference Stack Risk

high

Funding Intensity

3570%

$25M in preferred stock overhang against an unknown valuation; common equity at risk if exit below $25M.

Dilution Risk

high

Likely multiple future rounds due to early stage; typical Series A dilution ~20% per round.

Secondary Liquidity

none

No secondary market indicated; no recent secondary transactions.

Questions to Ask at the Interview

Strategic questions based on Arya Health's data — designed to show you've done your homework.

  • 1

    How does your AI agent handle interoperability with legacy EMR systems?

  • 2

    What is your current ARR and growth rate?

  • 3

    What is the expected timeline to next funding round or liquidity event?

Community

Valuation Sentiment

Our model estimates 0% upside. What do you think?

Anonymous. Do not share material non-public information.


Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.